Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235447 | 1.00 | — | — | |
| SCHEMBL8421142 | 1.00 | ALDH1A1 (0.36) | ALDH1A1FUCA1CYP2C9TSHRCYP2C19 | |
| SCHEMBL16924872 | 1.00 | ALDH1A1 (0.36) | ALDH1A1FUCA1CYP2C9TSHRCYP2C19 | |
| SCHEMBL2453706 | 1.00 | — | — | |
| SCHEMBL20893 | 1.00 | — | — | |
| SCHEMBL23802873 | 1.00 | ALDH1A1 (0.36) | ALDH1A1FUCA1CYP2C9TSHRCYP2C19 | |
| SCHEMBL101769 | 1.00 | — | — | |
| SCHEMBL6368791 | 1.00 | — | — | |
| SCHEMBL235448 | 1.00 | — | — | |
| SCHEMBL6742951 | 1.00 | ALDH1A1 (0.36) | ALDH1A1FUCA1CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772401-A | High-temperature-resistant polymer, high-temperature-resistant polymer film and lithium battery | 中国科学院长春应用化学研究所 | 2024-10-15 | — | — | CN | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-115911573-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-11367899-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-06-21 | — | — | US | disclosed |
| CN-106848406-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111048841-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-105633345-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-10468720-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-2418723-A1 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | Mitsubishi Chemical Corporation (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2378602-A2 | Nonaqueous electrolyte for recherable battery, and recharchable battery with nonaqueous electrolyte | Mitsubishi Chemical Corporation (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100119956-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2144321-A1 | NONAQUEOUS ELECTROLYTE FOR RECHARGEABLE BATTERY, AND RECHARGEABLE BATTERY WITH NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-01-13 | — | — | EP | disclosed |
| EP-1409024-B1 | MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES | BAYER SCHERING PHARMA AG (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | ALDH1A1 2758/4885FUCA1 698/4885CYP2C9 4610/4885 |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | ALDH1A1 2758/4885FUCA1 698/4885CYP2C9 4610/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | ALDH1A1 3392/4885FUCA1 483/4885CYP2C9 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.